Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTSIUJ9)

• DTT Name: Interferon-alpha 2 (IFNA2)
• Synonyms: LeIF A; Interferon alphaA; Interferon alpha2; Interferon alpha-A; Interferon alpha-2; IFNalpha2; IFNA2C; IFNA2B; IFNA2A; IFN-alpha-2
• Gene Name: IFNA2
• DTT Type: Successful target; [1]
• BioChemical Class: Cytokine: interferon
• UniProt ID: IFNA2_HUMAN
• TTD ID: T63934
• Sequence:
  MALTFALLVALLVLSCKSSCSVGCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFG
  FPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEA
  CVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNL
  QESLRSKE
• Function: Produced by macrophages, IFN-alpha have antiviral activities.
• KEGG Pathway:
  Cytokine-cytokine receptor interaction (hsa04060)
  Regulation of autophagy (hsa04140)
  PI3K-Akt signaling pathway (hsa04151)
  Toll-like receptor signaling pathway (hsa04620)
  RIG-I-like receptor signaling pathway (hsa04622)
  Cytosolic DNA-sensing pathway (hsa04623)
  Jak-STAT signaling pathway (hsa04630)
  Natural killer cell mediated cytotoxicity (hsa04650)
  Tuberculosis (hsa05152)
  Hepatitis C (hsa05160)
  Hepatitis B (hsa05161)
  Measles (hsa05162)
  Influenza A (hsa05164)
  Herpes simplex infection (hsa05168)
  Autoimmune thyroid disease (hsa05320)
• Reactome Pathway:
  Regulation of IFNA signaling (R-HSA-912694)
  TRAF6 mediated IRF7 activation (R-HSA-933541)
  Factors involved in megakaryocyte development and platelet production (R-HSA-983231)
  Interferon alpha/beta signaling (R-HSA-909733)

Molecular Interaction Atlas (MIA) of This DTT

3 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Interferon Alfa-2b	DMWCQP4	Melanoma	2C30	Approved	[1]
Peginterferon alfa-2a	DMJI3BA	Chronic hepatitis B virus infection		Approved	[1]
Peginterferon alfa-2b	DMAP58Y	Hepatitis C virus infection	1E51.1	Approved	[1]

9 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Albinterferon alfa-2b	DMK0QW6	Hepatitis C virus infection	1E51.1	Phase 3	[2]
Hebergel	DMQTLVB	Virus infection	1A24-1D9Z	Phase 3	[3]
Interferon alpha 2a	DMOTH6V	Hepatitis C virus infection	1E51.1	Phase 3	[4]
P-1101	DM7WYXJ	Essential thrombocythemia	3B63.1Z	Phase 3	[5]
Instiladrin	DMNKAFQ	Bladder cancer	2C94	Phase 2	[6]
Interferon alpha-2b	DMVACTU	Hepatitis C virus infection	1E51.1	Phase 2	[7]
Novaferon	DMEHOI1	Colorectal cancer	2B91.Z	Phase 2	[8]
CIGB-128	DMB2MKU	Basal cell carcinoma	2C32	Phase 1	[9]
SCH-721015	DMDP6UF	Mesothelioma	2C51.2	Phase 1	[10]

2 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HAp-IFN	DM9K6H5	Hepatitis C virus infection	1E51.1	Investigative	[11]
subalin	DMKH9IE	Discovery agent	N.A.	Investigative	[12]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Bladder cancer	2C82	Bladder tissue	9.31E-04	0.35	2.05
Rectal cancer	2C82	Rectal colon tissue	3.04E-01	-0.17	-0.73
Melanoma	2C82	Skin	3.08E-01	-0.16	-0.42

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [2] Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009 Apr;25(4):991-1002.
• [3] Evaluation of recombinant human interferon alpha-2b structure and stability by in-gel tryptic digestion, H/D exchange and mass spectrometry. J Pharm Biomed Anal. 2006 Feb 24;40(3):781-7.
• [4] Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment. Blood. 1988 Aug;72(2):655-60.
• [5] Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010 Aug;96(4):703-8.
• [6] ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of Avarx.
• [8] Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo. Cancer Cell Int. 2014; 14: 8.
• [9] Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
• [10] Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys. Gene Ther. 2012 Jul;19(7):742-51.
• [11] CN patent application no. 1921880, Protein drug sustained-release microparticle preparation for injection and process for producing the same.
• [12] [Adjuvant properties of subalin, a recombinant interferon-producing probiotic].Zh Mikrobiol Epidemiol Immunobiol.2001 Nov-Dec;(6):77-82.